{"nctId":"NCT02229383","briefTitle":"Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus","startDateStruct":{"date":"2014-09-06","type":"ACTUAL"},"conditions":["Diabetes Mellitus"],"count":464,"armGroups":[{"label":"Exenatide","type":"EXPERIMENTAL","interventionNames":["Drug: Exenatide"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Exenatide matching placebo"]}],"interventions":[{"name":"Exenatide","otherNames":[]},{"name":"Exenatide matching placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Has a diagnosis of Type 2 Diabetes Mellitus (T2DM)\n* Has HbA1c of 7.5% to 12.0%, inclusive, at Visit 1 (Screening).\n* Has fasting plasma glucose (FPG) concentration \\<280 mg/dL (15.6 mmol/L) at Visit 1 (Screening)\n* Treated with basal insulin glargine at a dose of ≥20 units/day once daily for at least 6 weeks prior to Screening, in combination with diet and exercise alone or in combination with:\n\n  1. a stable dose of metformin (≥1500 mg/day) for at least 8 weeks prior to Visit 1\n  2. a stable dose of metformin (≥1500 mg/day) for at least 8 weeks prior to Visit 1 (Screening) and a stable dose of sulfonylurea for at least 8 weeks prior to the Screening visit\n\nExclusion criteria:\n\n* Serum calcitonin concentration ≥40 pg/mL (≥40 ng/L) at Visit 1 (Screening)\n* History of, or currently have, acute or chronic pancreatitis, or have triglyceride concentrations ≥500 mg/dL (≥5.65 mmol/L) at Visit 1\n* Positive serological test for hepatitis B or hepatitis C","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"130 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in HbA1c From Baseline to Week 28","description":"To compare the change from baseline in HbA1c achieved with exenatide once weekly (EQW) added to titrated basal insulin glargine to placebo added to titrated basal insulin glargine, with or without metformin, after 28 weeks of double-blind treatment. SU= sulfonylurea.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.96","spread":null},{"groupId":"OG001","value":"-0.22","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight From Baseline to Week 28","description":"To compare the change from baseline in body weight achieved with EQW added to titrated basal insulin glargine to placebo added to titrated basal insulin glargine, with or without metformin, after 28 weeks of double-blind treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.04","spread":null},{"groupId":"OG001","value":"0.48","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 28 in 2-hour Postprandial Glucose After a Standard Meal Tolerance Test (MTT)","description":"To compare the change from baseline in 2-hour postprandial glucose after a standard MTT achieved with EQW added to titrated basal insulin glargine to placebo added to titrated basal insulin glargine, with or without metformin, after 28 weeks of double-blind treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.73","spread":null},{"groupId":"OG001","value":"-0.96","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving HbA1c <7.0% at Week 28","description":"To compare the percentage of participants achieving HbA1c \\<7.0% between EQW added to titrated basal insulin glargine to placebo added to titrated basal insulin glargine, with or without metformin, after 28 weeks of double-blind treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.6","spread":null},{"groupId":"OG001","value":"7.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 28 in Daily Insulin Dose","description":"To compare the change from baseline in daily insulin dose achieved with EQW added to titrated basal insulin glargine to placebo added to titrated basal insulin glargine, with or without metformin, after 28 weeks of double-blind treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null},{"groupId":"OG001","value":"3.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving HbA1c <7.0% at Week 28, No Weight Gain at Week 28, and No Major Hypoglycemia Over 28 Weeks","description":"To compare the percentage of participants achieving HbA1c \\<7.0% at Week 28, no weight gain at Week 28, and no major hypoglycemia over 28 weeks between EQW added to titrated basal insulin glargine to placebo added to titrated basal insulin glargine, with or without metformin.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.2","spread":null},{"groupId":"OG001","value":"2.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Seated Systolic Blood Pressure From Baseline to Week 28","description":"To compare the change from baseline in seated systolic blood pressure achieved with EQW added to titrated basal insulin glargine to placebo added to titrated basal insulin glargine, with or without metformin, after 28 weeks of double-blind treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":null},{"groupId":"OG001","value":"-0.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":231},"commonTop":["Urinary tract infection","Nausea","Blood creatine phosphokinase increased","Injection site nodule"]}}}